


Apple. No. : 08/779,767
Filed : 1/7/1997

REMARKS

Claims 4, 6, 9, 11, 24, 26 - 27, 29, 66 - 70 and 72 - 74 stand rejected under 35 USC 112(1) for lack of enablement. Applicant has amended claim 66 to clarify that the described composition inactivates autoreactive T cells. Applicant believes that the amendment to claim 66 clarifies the scope of the claims and the rejected claims are now allowable. A version of claim 66 with markings to show changes to the claim is attached.

Applicant is filing a response within two months of the date of the Office Action and thus no fee is believed to be required. However, the Commissioner is hereby authorized to charge any required fees to deposit account no. 01-1008. If there are any questions, applicant's attorney may be reached

Dated: 12/17/02

By: 
John Wurst
Registration No. 40,283
(858) 410-5174

Apple. No. : 08/779,767
Filed : 1/7/1997

VERSION WITH MARKINGS TO SHOW CLAIM CHANGES

66. A composition comprising an immunoglobulin or a portion thereof linked to a protein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and said protein fragment or peptide comprises a T cell receptor antagonist, said composition having the property of being endocytosed by cells bearing said Fc receptor and processed by the cells to present said T cell receptor antagonist in association with endogenous MHC Class II molecules, thereby preventing [T cell] activation of autoreactive T cells *in vivo*.